Optimal platform for drug efficacy and predictive toxicology screening


The pharmaceutical industry is in high need of efficient and relevant in vitro liver models, which can be incorporated in their drug discovery pipelines to identify potential drugs and their toxicity profiles.

Current liver models often rely on cancer cell lines or primary cells, which both have major limitations. The development of human induced pluripotent stem cells (iPSCs) has created a new opportunity for liver disease modelling, drug discovery and liver toxicity research.

DefiniGEN’s highly developed iPSC-derived hepatocyte-like cells,  Opti-HEPs, bridge this gap and serve as an optimal platform for drug efficacy and predictive toxicology screening.

DefiniGEN Opti-HEP have been extensively characterised in response to all the above criteria, revealing their highly metabolic functionality and superiority to existing pre-clinical liver models

Frequently asked questions

Do Opti-HEPs express ASGR1?

Yes, ASGR1 and ASGR2 has been detected by qPCR analysis and ICC and has been shown to localize on the cell membrane. 

Do they have a functional urea cycle?

Yes this has been characterized by gene expression profiling, Western blot analysis and Ornithine stimulated functional analysis.

Can you see CYP expression activity?

Expression of CYPs is detectable by qPCR analysis, but they are lower than Primary Human Hepatocytes (PHH).